ORGANOGENESIS HOLDINGS INC. Lease, Cost
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Lease, Cost of $23.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. lease, cost for the quarter ending 2024-06-30 was $4.02M, a 17.41% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. lease, cost for the quarter ending 2024-03-31 was $4.33M, a 10.49% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. lease, cost for the quarter ending 2023-12-31 was $4.39M, a 5.83% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. lease, cost for the quarter ending 2023-09-30 was $5.08M, a 11.98% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. lease, cost for fiscal 2025 was $23.20M, a 14.10% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. lease, cost for fiscal 2024 was $20.33M, a 5.97% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. lease, cost for fiscal 2023 was $19.18M, a 7.64% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. lease, cost for fiscal 2022 was $17.82M, a 2.25% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $23.20M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $20.33M 10-K · filed 2026-02-26 | |||
| 2024-06-30 | $4.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $8.35M 10-Q · filed 2024-08-08 | $12.74M derived: sum of 3 quarters · filed 2026-02-26 | $17.83M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $4.33M 10-Q · filed 2024-05-09 | $8.72M derived: sum of 2 quarters · filed 2026-02-26 | $13.81M derived: sum of 3 quarters · filed 2026-02-26 | $18.68M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $4.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.47M derived: sum of 2 quarters · filed 2026-02-26 | $14.34M derived: sum of 3 quarters · filed 2026-02-26 | $19.18M 10-K · filed 2026-02-26 |
| 2023-09-30 | $5.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $9.95M derived: sum of 2 quarters · filed 2024-08-08 | $14.79M 10-Q · filed 2023-11-09 | $19.46M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-06-30 | $4.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $9.71M 10-Q · filed 2024-08-08 | $14.37M derived: sum of 3 quarters · filed 2024-08-08 | $18.91M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.84M 10-Q · filed 2024-05-09 | $9.51M derived: sum of 2 quarters · filed 2024-05-09 | $14.05M derived: sum of 3 quarters · filed 2024-05-09 | $18.53M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $4.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $9.20M derived: sum of 2 quarters · filed 2024-02-29 | $13.69M derived: sum of 3 quarters · filed 2024-02-29 | $17.82M 10-K · filed 2024-02-29 |
| 2022-09-30 | $4.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $9.03M derived: sum of 2 quarters · filed 2023-11-09 | $13.16M 10-Q · filed 2023-11-09 | $17.52M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $4.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $8.62M 10-Q · filed 2023-08-09 | $12.98M derived: sum of 3 quarters · filed 2023-08-09 | $17.91M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $4.13M 10-Q · filed 2023-05-10 | $8.49M derived: sum of 2 quarters · filed 2023-05-10 | $13.42M derived: sum of 3 quarters · filed 2023-05-10 | $17.56M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $4.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $9.29M derived: sum of 2 quarters · filed 2023-03-01 | $13.42M derived: sum of 3 quarters · filed 2023-03-01 | $17.43M 10-K · filed 2023-03-01 |
| 2021-09-30 | $4.93M 10-Q · filed 2021-11-09 | $9.07M derived: sum of 2 quarters · filed 2021-11-09 | $13.07M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $4.14M 10-Q · filed 2021-08-09 | $8.14M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $4.01M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |